S. R. Schill & Associates raised its holdings in shares of AbbVie Inc (NYSE:ABBV) by 11.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 3,261 shares of the company’s stock after buying an additional 347 shares during the period. S. R. Schill & Associates’ holdings in AbbVie were worth $247,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of ABBV. Lavaca Capital LLC lifted its holdings in AbbVie by 69.2% during the 2nd quarter. Lavaca Capital LLC now owns 49,404 shares of the company’s stock valued at $3,593,000 after purchasing an additional 20,213 shares during the last quarter. Horseman Capital Management Ltd lifted its holdings in AbbVie by 45.5% during the 2nd quarter. Horseman Capital Management Ltd now owns 16,000 shares of the company’s stock valued at $1,164,000 after purchasing an additional 5,000 shares during the last quarter. Ironwood Investment Counsel LLC lifted its holdings in AbbVie by 7.9% during the 2nd quarter. Ironwood Investment Counsel LLC now owns 9,171 shares of the company’s stock valued at $666,000 after purchasing an additional 675 shares during the last quarter. Cedar Wealth Management LLC acquired a new stake in AbbVie during the 2nd quarter valued at $44,000. Finally, Ballentine Partners LLC lifted its holdings in AbbVie by 52.1% during the 2nd quarter. Ballentine Partners LLC now owns 12,168 shares of the company’s stock valued at $886,000 after purchasing an additional 4,169 shares during the last quarter. 68.22% of the stock is owned by institutional investors.
Shares of ABBV traded down $1.27 during midday trading on Thursday, reaching $76.48. 3,511,549 shares of the stock were exchanged, compared to its average volume of 7,437,319. AbbVie Inc has a twelve month low of $62.66 and a twelve month high of $94.98. The company has a market cap of $115.13 billion, a P/E ratio of 9.67, a PEG ratio of 1.59 and a beta of 0.99. The stock’s 50 day simple moving average is $72.73 and its 200 day simple moving average is $73.57.
The business also recently declared a — dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be given a $1.07 dividend. This represents a dividend yield of 6.4%. The ex-dividend date of this dividend is Friday, October 11th. AbbVie’s payout ratio is currently 54.11%.
In related news, EVP Timothy J. Richmond sold 15,515 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $75.02, for a total value of $1,163,935.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Henry O. Gosebruch purchased 30,000 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was bought at an average price of $67.28 per share, for a total transaction of $2,018,400.00. Following the transaction, the executive vice president now directly owns 75,763 shares of the company’s stock, valued at approximately $5,097,334.64. The disclosure for this purchase can be found here. Insiders purchased 183,077 shares of company stock worth $10,705,751 in the last 90 days. 0.08% of the stock is owned by company insiders.
Several brokerages have issued reports on ABBV. Piper Jaffray Companies raised their price target on AbbVie from $80.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. ValuEngine raised AbbVie from a “strong sell” rating to a “sell” rating in a report on Monday, September 30th. Wolfe Research raised AbbVie from an “underperform” rating to a “peer perform” rating in a report on Thursday, June 27th. UBS Group raised AbbVie from a “neutral” rating to a “buy” rating and dropped their target price for the stock from $85.00 to $79.00 in a report on Thursday, September 12th. Finally, TheStreet downgraded AbbVie from a “b-” rating to a “c” rating in a report on Monday, August 26th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $86.51.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Featured Article: Float
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.